|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
On the contrary, no link could be detected between expression of BRAF(V599E) and age at diagnosis, gender, dimension, and local invasiveness of the primary cancer, presence of lymph node metastases, tumor stage, and multifocality of the disease.
|
15126572 |
2004 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
On the contrary, no link could be detected between expression of BRAF(V599E) and age at diagnosis, gender, dimension, and local invasiveness of the primary cancer, presence of lymph node metastases, tumor stage, and multifocality of the disease.
|
15126572 |
2004 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In a series of 33 cases, 21 harbored the T1799A mutation in the primary tumors, and 17 (81%) of them harbored the same mutation also in the paired lymph node metastases.
|
15998781 |
2005 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
|
16179870 |
2005 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
|
16179870 |
2005 |
|
rs121913227
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
|
16179870 |
2005 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
While univariate analysis showed the BRAF(V600E) mutation was associated with tumour recurrence (21% with mutation vs 7% without mutation; P = 0.037), this association was not shown following multivariate analyses adjusting for the clinicopathological prognostic factors of age, gender, tumour size, extrathyroid extension, multifocality and lymph node metastasis.
|
16918957 |
2006 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
While univariate analysis showed the BRAF(V600E) mutation was associated with tumour recurrence (21% with mutation vs 7% without mutation; P = 0.037), this association was not shown following multivariate analyses adjusting for the clinicopathological prognostic factors of age, gender, tumour size, extrathyroid extension, multifocality and lymph node metastasis.
|
16918957 |
2006 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associated with older age (P = 0.0381), lymph node metastasis (P = 0.0323), distant metastasis (P = 0.045), higher TNM stage (I and II vs. III and IV, P = 0.0389), and recurrent and persistent disease (P = 0.009) with a median follow-up time of 6.0 years.
|
17717450 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, the BRAF (V600E) mutation in 54 PTCs was investigated and the relationship between the BRAF mutation and clinicopathological features such as age, gender, tumor size, extrathyroid extension, lymph node metastasis, and distant metastasis was analyzed.
|
17972530 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutational patterns identical to those in the primary tumors were found in 11/12 lymph node metastases (92%, including both BRAF(T1799A)-positive and -negative cases).
|
17044028 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
|
17685465 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, the BRAF (V600E) mutation in 54 PTCs was investigated and the relationship between the BRAF mutation and clinicopathological features such as age, gender, tumor size, extrathyroid extension, lymph node metastasis, and distant metastasis was analyzed.
|
17972530 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
|
17685465 |
2007 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associated with older age (P = 0.0381), lymph node metastasis (P = 0.0323), distant metastasis (P = 0.045), higher TNM stage (I and II vs. III and IV, P = 0.0389), and recurrent and persistent disease (P = 0.009) with a median follow-up time of 6.0 years.
|
17717450 |
2007 |
|
rs11225395
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Four of the SNPs were found to be associated with lymph node metastasis, the most pronounced being a promoter SNP (rs11225395) with its minor allele (T) associating with reduced susceptibility to lymph node metastasis (P = 0.02).
|
17974962 |
2007 |
|
rs699947
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The A allele of the SNP rs699947 increased the risk of thyroid cancer development and regional lymph node metastasis in men.
|
17951537 |
2007 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.
|
18470905 |
2008 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We analyzed the expression of S100A4, cyclin D1, p27 and MUC1, the presence of the BRAF V600E mutation and the clinicopathological features of the tumors, including patient age, tumor size (>or=5 vs <5 mm), extrathyroidal extension, multifocality, histological subtype, sclerosis and encapsulation, in a series of 198 papillary microcarcinomas in relation to lymph node metastasis to determine the predictive factors of lymph node metastasis.
|
18360353 |
2008 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We previously described a patient with BRAF V600E mutation in primary tumor and a new mutation (V600E+K601del) in the matched-lymph node metastases.
|
19169486 |
2008 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We previously described a patient with BRAF V600E mutation in primary tumor and a new mutation (V600E+K601del) in the matched-lymph node metastases.
|
19169486 |
2008 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We analyzed the expression of S100A4, cyclin D1, p27 and MUC1, the presence of the BRAF V600E mutation and the clinicopathological features of the tumors, including patient age, tumor size (>or=5 vs <5 mm), extrathyroidal extension, multifocality, histological subtype, sclerosis and encapsulation, in a series of 198 papillary microcarcinomas in relation to lymph node metastasis to determine the predictive factors of lymph node metastasis.
|
18360353 |
2008 |
|
rs1052133
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We observed a strong association between the G/C genotype of the RAD51-135 G/C polymorphism and the expression of the progesterone receptor and between both alleles of the OGG1-Ser326Cys polymorphism and lymph node metastasis.
|
18977234 |
2008 |
|
rs13181
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, the unfavorable genotype ERCC2 2251A>C (P = 0.006), tumor invasion depth (P = 0.025), lymph node metastasis (P = 0.011) and cancer stage (P = 0.008) were significantly correlated with early relapse.
|
18267032 |
2008 |
|
rs559635697
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the mutational analysis, we found one missense somatic mutation (CGG-->TGG, R275W) in the BTB/POZ domain of the gene in a patient with advanced gastric cancer and lymph node metastasis.
|
17906984 |
2008 |